Gastroesophageal Junction Adenocarcinoma Clinical Trials in Philadelphia, Pennsylvania

3 studies are recruiting for gastroesophageal junction adenocarcinoma in Philadelphia, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

    The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesophageal junction (GE…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Research Site, Philadelphia, Pennsylvania
    Locations
    311 in total
    Run by
    AstraZeneca

    See if you can join NCT07431281 on ClinicalTrials.gov

  2. Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

    This study is being done to answer the following questions: Can we lower the chance of your gastric cancer from growing or spreading by administering paclitaxel chemotherapy directly into your abdominal cavity in addition to chemotherapy given through a vein in your arm? Will administering paclitax…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
    Locations
    78 in total
    Run by
    ECOG-ACRIN Cancer Research Group

    See if you can join NCT07001748 on ClinicalTrials.gov

  3. Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma

    The goal of this study is to learn about of the research study drug, telomelysin (OBP-301), in combination with pembrolizumab in advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer. The main question it aims to answer is whether this combination is safe and effective in this ty…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania
    Locations
    2 in total
    Run by
    Weill Medical College of Cornell University

    See if you can join NCT06340711 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.